Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-02
2007-10-02
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S047000, C514S048000, C514S04400A, C536S023100, C536S023200, C536S023700, C536S023720, C536S023500, C536S024500, C536S023740
Reexamination Certificate
active
10279684
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5635377 (1997-06-01), Pederson et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 6476000 (2002-11-01), Agrawal
patent: 6815429 (2004-11-01), Agrawal
patent: 2004/0097719 (2004-05-01), Agrawal et al.
patent: 2004/0156825 (2004-08-01), Agrawal et al.
patent: 2004/0198685 (2004-10-01), Agrawal et al.
patent: 2005/0009773 (2005-01-01), Kandimalla et al.
patent: 2005/0026861 (2005-02-01), Kandimalla et al.
patent: 2005/0130911 (2005-06-01), Uhlmann et al.
patent: 2005/0130918 (2005-06-01), Agrawal et al.
patent: 2005/0222072 (2005-10-01), Wang et al.
patent: 2006/0014713 (2006-01-01), Agrawal et al.
patent: 2006/0019918 (2006-01-01), Agrawal et al.
patent: 2006/0019919 (2006-01-01), Agrawal et al.
patent: 2006/0025365 (2006-02-01), Agrawal et al.
patent: 2006/0074040 (2006-04-01), Kandimalla et al.
patent: 2006/0094681 (2006-05-01), Agrawal et al.
patent: 2006/0098680 (2006-05-01), Kelesoglu et al.
patent: 2006/0211641 (2006-09-01), Agrawal et al.
patent: 2006/0217328 (2006-09-01), Kandimalla et al.
patent: 2006/0241076 (2006-10-01), Uhlmann et al.
patent: 2006/0287261 (2006-12-01), Agrawal et al.
patent: 2006/0287262 (2006-12-01), Agrawal et al.
patent: 2007/0066554 (2007-03-01), Krieg et al.
patent: 1393745 (2004-02-01), None
patent: WO97/29757 (1997-08-01), None
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
patent: WO 01/55370 (2001-08-01), None
patent: WO 01/83503 (2001-11-01), None
patent: WO 02/26757 (2002-04-01), None
patent: WO03/000922 (2003-01-01), None
patent: WO03/035836 (2003-05-01), None
patent: WO 2004/064782 (2004-08-01), None
patent: WO 2004/103301 (2004-12-01), None
patent: WO 2005/009355 (2005-02-01), None
Yu et al, BBRC, 2002, 297:83-90.
Yu et al, Nucleic ACid Research, 2002, 30/20:4460-4469.
Yu et al, Bioorganic & Medicinal Chemistry Letters, 2000, 10:2585-2588.
Li et al, International Immnopharmacology, 2005, 5:981-991.
Zhu et al, International Immunopharmacology, 2004, 4:851-862.
Kandimalla et al, Current Opinion Molecular Therapeutics, 2002, 4/2:122-129.
Kandimalla et al, Bioconjugate Chem., 2002, 13:966-974.
Kandimalla et al, Nucleic Acid Research, 2003, 31/9:2393-2400.
Kandimalla et al, PNAS, USA, Nov. 25, 2003, 100/24:14303-14308.
Gurunathan et al, Annu. Rev. Immunol., 2000, 18:927-974.
Yu et al, Bioorganic & Medicinal Chemistry, 2001, 9:2803-2808.
Agrawal et al, Ccurrent Opinion Biotechonology, 1995, 6:12-19.
Jones et al, Bioconjugate Chem., 1994, 5:390-399.
Wongratanacheewin et al, Infection and Immunity, 2004, 72/8:4494-4502.
Kawaguchi et al, Biol. Pharm. Bull., 1995, 18/3:474-476.
Kandimalla et al, BBRC, 2003, 306:948-953.
Bhagat et al, BBRC, 2003, 300:853-861.
Agrawal et al, International Immunopharmacology, 2004, 4:127-138.
Donnelly et al, Nature Medicine, 2003, 9/11:1354-1356.
DeGruijl et al, Nature Medicine, 1999, 5/10: 1124-1125.
Bitton, Current Opinion in Molecular Therapeutics, 2004, 6/1:17-25.
Agrawal et al, TRENDS in Molecular Medicine, 2002, 8/3:114-120.
Weiner, J. Leukocyte Biology, 2000, 68:455-463.
Kandimalla et al, PNAS, USA, May 10, 2005, 102/19:6925-6930.
Agrawal et al, Ann N.y. Acad. Sci., 2003, 1002:30-42.
Bjersing et al, Inflammation, 2004, 28/3:159-168.
Agrawal et al., “Protocols for Oilgonucleotides and Analogs”, Methods in Molecular Biology, 20:165-189, 1993.
Uhlmann et al., Oligonucleotides and Analogues, a Practical Approach, pp. 87-108, 1991.
Agrawal et al., Curr. Op. in biotech., 6:12, 1995.
Crooke et al., Antisense Research and Applications, CRC Press, Boca Raton, 1993.
Khorana et al., J. Molec. Biol., 72:209, 1972.
Reese, Tetrahedron Lett., 34:3143-3179, 1978.
Beaucage et al., Tetrahedron Lett. 22:1859-1862, 1981.
Agrawal et al., Tetrahedron Lett., 28:3539-3542, 1987.
Connolly et al., Biochem., 23:3443, 1984.
Jager et al., Biochem., 27:7237, 1988.
Agrawal et al., Proc. Natl. Acad. Sci. (USA), 85:7079-7083, 1988.
Kuramoto et al., Jpn. J. Cancer Res., 83:1128-1131, 1992.
Krieg et al., Nature, 371:546-549, 1995.
Liang et al., J. Clin. Invest., 98:1119-1129, 1996.
Moldoveanu et al., Vaccine, 16:1216-124, 1998.
McCluskie et al., J. Immunol., 161:4463-4466, 1998.
Zhao et al., Biochem. Pharmacol., 51:173-182, 1996.
Zhao et al., Biochem. Pharmacol., 52:1537-1544, 1996.
Zhao et al., Antisense Nucleic Acid Drug Dev., 7:495-502, 1997.
Zhao et al., Bioorg. Med. Chem. Lett., 9:3453-3458, 1999.
Zhao et al., Bioorg. Med. Chem. Lett., 10:1051-1054, 2000.
Yu et al., Bioorg. Med. Chem. Lett., 10:2585-2588, 2000.
Yu et al., Bioorg. Med. Chem. Lett. 11:2263-2267, 2001.
Kandimalla et al., Bioorg. Med. Chem., 9:807-813, 2001.
Remington's Pharmaceutical Sciences, 18thEdition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990.
Noronha et al., Biochem., 39:7050-7062, 2000.
International Search Report issued in corresponding PCT application PCT/US02/34247.
European Search Report issued in corresponding European application 03017211.8.
Agrawal Sudhir
Bhagat Lakshmi
Kandimalla Ekambar R.
Yu Dong
Idera Pharmaceuticals Inc.
Keown Wayne A.
Keown & Zucchero, LLP
Minnifield N. M.
Zucchero Joseph C.
LandOfFree
Modulation of immunostimulatory properties of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immunostimulatory properties of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immunostimulatory properties of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3902311